Trial reportEuropean journal of nuclear medicine and molecular imaging2022
Trial report in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use ofClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Guideline
- Assessment of the therapeutic efficacy of [European journal of nuclear medicine and molecular imaging · 2025Pooled it
- Joint EANM/SNMMI procedure guideline for the use ofEuropean journal of nuclear medicine and molecular imaging · 2023Guideline
- Efficacy, safety, and quality of life outcomes of [International urology and nephrology · 2026Review
- Insights from PSMAfore: impact on health-related quality of life.Translational andrology and urology · 2026Article
- FDG/PSMA discordance in [Frontiers in oncology · 2026Review
- Bellmunt risk score enables survival prediction in men with metastatic castration resistant prostate cancer (mCRPC) undergoing PSMA-targeted radioligand therapy (LUMEN).European journal of nuclear medicine and molecular imaging · 2026Article
- Theranostics 2.0: Target-driven, artificial intelligence-enabled cancer therapy across tumor types.Diagnostic and interventional imaging · 2025Review
- Sequencing of Radium-223 and Lutetium-177 Vipivotide Tetraxetan: Maximizing the Benefit of Systemic Targeted Radiation Therapy in Metastatic Castration-Resistant Prostate Cancer.Oncology and therapy · 2025Review
- Cost-utility analysis ofEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Bridging the Gap: PSMA Radioligand Therapy for Asian Men with Prostate Cancer.Nuclear medicine and molecular imaging · 2025Review
- Hematologic dysfunction and myeloid neoplasm risk in patients treated with lutetiumHaematologica · 2025Article
- Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey.Prostate cancer and prostatic diseases · 2025Review
- Evaluating the Efficacy and Safety of Pluvicto in Chemotherapy-Ineligible Nonagenarians: A Descriptive Case Series.Cureus · 2025Article
- Advances in PSMA-Targeted Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.Cancer management and research · 2025Review
- Current status of radionuclide therapies in metastatic castration-resistant prostate cancer.Therapeutic advances in medical oncology · 2025Review
- Review
- [European journal of nuclear medicine and molecular imaging · 2024Article
- Role of Lutetium Radioligand Therapy in Prostate Cancer.Cancers · 2024Review
- Advancements in PSMA ligand radiolabeling for diagnosis and treatment of prostate cancer: a systematic review.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLutetium-177 prostate-specific membrane antigen-617 (
methodsThis was a randomized, parallel-group, open-label, phase 2, and non-inferiority trial. Chemotherapy-naïve patients with mCRPC and high PSMA-expressing lesions on
resultsBetween December 2019 and March 2021, 40 of the 45 patients assessed for eligibility underwent randomization. Fifteen of 20 patients in
conclusionCLINICAL
trial registrationClinical Trials Registry-India, CTRI/2019/12/022282.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.